A prospective assessment of cytomegalovirus immune evasion gene transcription profiles in transplant patients with cytomegalovirus infection

Transplantation

Volumn 83, Issue 9, 2007, Pages 1200-1206

  Humar, Atul ^a,d   Kumar, Deepali ^a   Gray, Michael ^b   Moussa, George ^a   Venkataraman, Srividhya ^a   Kumar, Raahul ^a   Tipples, Graham A ^b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^c UNIVERSITY OF MANITOBA   (Canada)

^d TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

Cytomegalovirus; Immune evasion; Viremia

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; DNA; GANCICLOVIR; LYMPHOCYTE ANTIBODY; MESSENGER RNA; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS; VALGANCICLOVIR;

ANTIVIRAL THERAPY; ARTICLE; CALCULATION; CLINICAL ASSESSMENT; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; GENE EXPRESSION PROFILING; GENETIC TRANSCRIPTION; GRAFT VERSUS HOST REACTION; HALF LIFE TIME; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KINETICS; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; ORGAN TRANSPLANTATION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REINFECTION; RELAPSE; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; VIREMIA; VIROLOGY; VIRUS IMMUNITY; VIRUS LOAD;

ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; GLYCOPROTEINS; HUMANS; IMMEDIATE-EARLY PROTEINS; IMMUNE TOLERANCE; IMMUNOSUPPRESSION; KINETICS; MEMBRANE PROTEINS; ORGAN TRANSPLANTATION; PROSPECTIVE STUDIES; RECURRENCE; RNA, MESSENGER; RNA-BINDING PROTEINS; TIME FACTORS; VIRAL PROTEINS;

EID: 34248340014     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000261105.34233.4f     Document Type: Article

References (29)

1. Gandhi MK, Khanna R. Human cytomegalovirus: Clinical aspects, immune regulation, and emerging treatments. Lancet Infect Dis 2004; 4: 725.
2. American Society of Transplantation, Infectious Disease Community of Practice. Guidelines for the prevention and management of infectious complications of solid organ transplantation. Preiksaitis JK, Avery RK, Green M, eds. Am J Transplant 2004; Suppl 10: 51.
3. Preiksaitis JK, Brennan DC, Fishman J, Allen U. Canadian society of transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report. Am J Transplant 2005; 5: 218.
4. Paya CV, Razonable RR. Cytomegalovirus infection after organ transplantation. In: Bowden RA, Ljungman P, Paya CV, eds. Transplant Infections. Baltimore: Lippincott Williams & Wilkins; 1998.
5. Humar A, Kumar D, Boivin G, Caliendo AM. Cytomegalovirus (CMV) virus load kinetics to predict recurrent disease in solid-organ transplant patients with CMV disease. J Infect Dis 2002; 186: 829.
6. Sia IG, Wilson JA, Groettum CM, et al. Cytomegalovirus (CMV) DNA load predicts relapsing CMV infection after solid organ transplantation. J Infect Dis 2000; 181: 717.
7. Humar A, Uknis M, Carlone-Jambor C, et al. Cytomegalovirus disease recurrence after ganciclovir treatment in kidney and kidney-pancreas transplant recipients. Transplantation 1999; 67: 94.
8. Rasmussen L. Molecular pathogenesis of human cytomegalovirus infection. Transpl Infect Dis 1999; 1: 127.
9. Mocarski ES. Immune escape and exploitation strategies of cytomegaloviruses: Impact on and imitation of the major histocompatibility system. Cell Microbiol 2004; 6: 707.
10. Basta S, Bennink JR. A survival game of hide and seek: Cytomegaloviruses and MHC class I antigen presentation pathways. Viral Immunol 2003; 16: 231.
11. Hegde NR, Chevalier MS, Johnson DC. Viral inhibition of MHC class II antigen presentation. Trends Immunol 2003; 24: 278.
12. Hegde NR, Johnson DC. Human cytomegalovirus US2 causes similar effects on both major histocompatibility complex class I and II proteins in epithelial and glial cells. J Virol 2003; 77: 9287.
13. Jones TR, Hanson LK, Sun L, et al. Multiple independent loci within the human cytomegalovirus unique short region down-regulate expression of major histocompatibility complex class I heavy chains. J Virol 1995; 69: 4830.
14. Park B, Kim Y, Shin J, et al. Human cytomegalovirus inhibits tapasin-dependent peptide loading and optimization of the MHC class I peptide cargo for immune evasion. Immunity 2004; 20: 71.
15. van der Wal FJ, Kikkert M, Wiertz E. The HCMV gene products US2 and US11 target MHC class I molecules for degradation in the cytosol. Curr Top Microbiol Immunol 2002; 269: 37.
16. Momburg F, Hengel H. Corking the bottleneck: The transporter associated with antigen processing as a target for immune subversion by viruses. Curr Top Microbiol Immunol 2002; 269: 57.
17. Humar A, Michaels M. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant 2006; 6: 262.
18. Safronetz D, Humar A, Tipples GA. Differentiation and quantification of human herpesvirus 6A, 6B and 7 by real-time PCR. J Virol Methods 2003; 112: 99.
19. Radonic A, Thulke S, Mackay IM, et al. Guideline to reference gene selection for quantitative real-time PCR. Biochem Biophys Res Commun 2004; 313: 856.
20. Roberts TC, Brennan DC, Buller RS, et al. Quantitative polymerase chain reaction to predict occurrence of symptomatic cytomegalovirus infection and assess response to ganciclovir therapy in renal transplant patients. J Infect Dis 1998; 178: 626.
21. Furman MH, Dey N, Tortorella D, Ploegh HL. The human cytomegalovirus US10 gene product delays trafficking of major histocompatibility complex class I molecules. J Virol 2002; 76: 11753.
22. Zhao Y, Biegalke BJ. Functional analysis of the human cytomegalovirus immune evasion protein, pUS3(22kDa). Virology 2003; 315: 353.
23. Ahn K, Gruhler A, Galocha B, et al. The ER-luminal domain of the HCMV glycoprotein US6 inhibits peptide translocation by TAP. Immunity 1997; 6: 613.
24. Tomazin R, Boname J, Hegde NR, et al. Cytomegalovirus US2 destroys two components of the MHC class II pathway, preventing recognition by CD4+ T cells. Nat Med 1999; 5: 1039.
25. Greijer AE, Verschuuren EA, Dekkers CA, et al. Expression dynamics of human cytomegalovirus immune evasion genes US3, US6, and US11 in the blood of lung transplant recipients. J Infect Dis 2001; 184: 247.
26. Tomasec P, Wang EC, Davison AJ, et al. Downregulation of natural killer cell-activating ligand CD155 by human cytomegalovirus UL141. Nat Immunol 2005; 6: 181.
27. Boomker JM, van Luyn MJ, The TH, et al. US28 actions in HCMV infection: Lessons from a versatile hijacker. Rev Med Virol 2005; 15: 269.
28. Boomker JM, Verschuuren EA, Brinker MG, et al. Kinetics of US28 gene expression during active human cytomegalovirus infection in lung-transplant recipients. J Infect Dis 2006; 193: 1552.
29. Raftery MJ, Wieland D, Gronewald S, et al. Shaping phenotype, function, and survival of dendritic cells by cytomegalovirus-encoded IL-10. J Immunol 2004; 173: 3383.